Harvard-Allston Task Force/180 Western Avenue Impact Advisory Group Meeting

Jan 26, 2021

6:00 PM - 7:30 PM
Rss
  • Contact Name:

    Nupoor Monani

  • Contact Email Address:

    [email protected]

  • Type:

    Impact Advisory Group (IAG)

  • Location:

    Virtual Meeting

  • Contact Phone:

    617.918.4425

Description:

Meeting of the combined Harvard-Allston Task Force and Impact Advisory Group (IAG) for the 180 Western Avenue development in Allston. The Task Force serves as the advisory body for Harvard's institutional development, the Enterprise Research Campus, and 180 Western Avenue. This meeting will be focused on the proposed development at 180 Western Avenue.

Please note that the purpose of this meeting is different than that of a traditional community meeting. As part of the development review process, Task Force members work closely with BPDA staff to identify the impacts of a project and recommend appropriate mitigation measures and/or community benefits to offset those impacts. Task Force meetings prioritize discussion between the project proponent (i.e. the developer) and Task Force members. As such, comments from the public will be limited to the last 15 minutes.

How to Participate

This meeting will be hosted online, using Zoom. Register using this link, then you will receive a confirmation email with instructions for joining the meeting. You will also receive an email prior to the meeting regarding technical assistance. The meeting will open 15 minutes before 6:00 PM for you to join and troubleshoot any technical issues. If you're calling in by phone, you'll need to download the Zoom application to see our presentation.

Register in advance for this meeting:
bit.ly/3o7YxY8

Toll free call in number: 833 568 886
Meeting ID: 161 256 5534

Due to the COVID-19 public health emergency, the Boston Planning & Development Agency (BPDA) has postponed all in-person BPDA-held public meetings regarding Article 80 development projects and planning initiatives. View more information on the BPDA's COVID-19 response.